Cognition Therapeutics (NASDAQ:CGTX) Earns Buy Rating from HC Wainwright

Cognition Therapeutics (NASDAQ:CGTX)‘s stock had its “buy” rating reiterated by stock analysts at HC Wainwright in a report issued on Wednesday,Benzinga reports. They presently have a $5.00 price target on the stock.

A number of other research analysts also recently commented on the company. B. Riley reaffirmed a “neutral” rating and set a $1.00 target price (down previously from $5.00) on shares of Cognition Therapeutics in a report on Tuesday, August 6th. Chardan Capital reissued a “buy” rating and issued a $11.00 price target on shares of Cognition Therapeutics in a report on Friday, November 15th. Finally, Cantor Fitzgerald downgraded Cognition Therapeutics from an “overweight” rating to a “neutral” rating in a report on Tuesday, July 30th. Two equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $8.00.

Cognition Therapeutics Price Performance

Cognition Therapeutics stock opened at $0.40 on Wednesday. Cognition Therapeutics has a 12 month low of $0.34 and a 12 month high of $2.95. The company has a market cap of $16.81 million, a price-to-earnings ratio of -0.42 and a beta of 1.34. The stock’s 50-day moving average is $0.48 and its 200-day moving average is $1.12.

Institutional Trading of Cognition Therapeutics

Hedge funds have recently added to or reduced their stakes in the business. Virtu Financial LLC acquired a new position in shares of Cognition Therapeutics during the 3rd quarter valued at $27,000. Sigma Planning Corp increased its position in shares of Cognition Therapeutics by 14.6% during the 3rd quarter. Sigma Planning Corp now owns 197,190 shares of the company’s stock valued at $92,000 after purchasing an additional 25,050 shares during the period. Mercer Global Advisors Inc. ADV increased its position in shares of Cognition Therapeutics by 33.4% during the 2nd quarter. Mercer Global Advisors Inc. ADV now owns 95,951 shares of the company’s stock valued at $159,000 after purchasing an additional 24,050 shares during the period. CM Management LLC increased its position in shares of Cognition Therapeutics by 14.3% during the 2nd quarter. CM Management LLC now owns 200,000 shares of the company’s stock valued at $332,000 after purchasing an additional 25,000 shares during the period. Finally, Bangor Savings Bank increased its position in shares of Cognition Therapeutics by 41.6% during the 2nd quarter. Bangor Savings Bank now owns 34,019 shares of the company’s stock valued at $56,000 after purchasing an additional 10,000 shares during the period. Institutional investors own 43.35% of the company’s stock.

Cognition Therapeutics Company Profile

Cognition Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, an orally delivered molecule modulator designed to penetrate the blood-brain barrier and bind selectively to the S2R complex, which is in Phase 2 clinical trial for the treatment of Alzheimer's disease, as well as geographic atrophy secondary to dry age-related macular degeneration and synucleinopathies, such as dementia with Lewy bodies.